EU Under Fire Over Handling Of COVID-19 Vaccine Procurement
Commission Defends Itself But Accepts Court of Auditors’ Recommendations
Executive Summary
The European Commission has come in for criticism over the way it handled the procurement of COVID-19 vaccines in the initial stages of the pandemic, particularly the lack of provisions in contracts with manufacturers regarding possible supply disruptions.
You may also be interested in...
EU Seeking Firms To Offer ‘Ever-Warm’ Production Capacity For Future Pandemics
The EU is drawing on lessons learned during the COVID-19 pandemic to set up a network of vaccine production capacities able to respond quickly to a surge in demand.
Coronavirus Notebook: EU Launches Vaccine Monitoring Scheme, AZ Vows To Defend Itself Against Legal Action
The EMA has issued updated safety advice on AstraZeneca’s COVID-19 vaccine, Vaxzevria, Valneva has decided to pursue vaccine supply deals with individual member states after a falling out with the European Commission, and Kazakhstan has begun administering the first doses of its domestically produced vaccine, QazVac.
National Drug Stockpiles Create ‘False Sense Of Security’
The generics and biosimilars industry body Medicines for Europe says disparate national stockpiling requirements are not a solution to shortages and can bring “significant risks” for the supply chain and access to medicines.